Theoretically, these puzzle pieces may come together in a pathway where CD82 negatively regulates p38 MAPK signaling and increase the expression of EZH2, which decreases MMP9 expressions in AML cells (Fig 5). The gene discussed is CD82; the disease is acute myeloid leukemia.